Their DSMB meeting and deciding to expand the number of subjects from 300 to 500+ doesn't lend confidence, either. On the other hand 37% improvement in recoveries on lenzilumab versus placebo sounds decent.
Lenzilumab trial overview is here:
I didn't realize how many other anti-GM-CSF trials were going on for Covid, but there seem to be quite a few, all with different endpoints:
We are doing a non-lenzilumab anti-GM-CSF trial for Covid at my hospital system, which came through our IRB recently. It has a 43 day mortality primary endpoint.
Lots of different trials for Covid.
Hopefully leronlimab will enroll quickly and be one of the best.